Atm sequence variants are predictive of adverse radiotherapy response among patients treated for prostate cancer

2004 ◽  
Vol 60 (1) ◽  
pp. S325
Author(s):  
J.A. Cesaretti ◽  
R.G. Stock ◽  
D.A. Atencio ◽  
J.L. Bernstein ◽  
N.N. Stone ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Sequence Variants

1075: ATM Sequence Variants are Predictive of the Development of Erectile Dysfunction Among Patients Treated for Prostate Cancer with 125Iodine Brachytherapy

2005 ◽  
Vol 173 (4S) ◽  
pp. 291-292
Author(s):  
Jamie A. Cesaretti ◽  
Richard G. Stock ◽  
Nelson N. Stone ◽  
Steven Lehrer ◽  
David A. Atencio ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Erectile Dysfunction ◽  
Sequence Variants

scholarly journals Toll-like receptor-associated sequence variants and prostate cancer risk among men of African descent

2013 ◽  
Vol 14 (6) ◽  
pp. 347-355 ◽  
Author(s):  
E N Rogers ◽  
D Z Jones ◽  
N C Kidd ◽  
S Yeyeodu ◽  
G Brock ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Risk ◽  
African Descent ◽  
Prostate Cancer Risk ◽  
Sequence Variants ◽  
Toll Like Receptor

scholarly journals Phosphodiesterase sequence variants may predispose to prostate cancer

2015 ◽  
Vol 22 (4) ◽  
pp. 519-530 ◽  
Author(s):  
Rodrigo B de Alexandre ◽  
Anelia D Horvath ◽  
Eva Szarek ◽  
Allison D Manning ◽  
Leticia F Leal ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Immunohistochemical Analysis ◽  
Cyclic Guanosine Monophosphate ◽  
Genome Project ◽  
Guanosine Monophosphate ◽  
Sequence Variants ◽  
Sequencing Data ◽  
Sequence Variations ◽  
Novel Variants ◽  
Somatic State

We hypothesized that mutations that inactivate phosphodiesterase (PDE) activity and lead to increased cAMP and cyclic guanosine monophosphate levels may be associated with prostate cancer (PCa). We sequenced the entire PDE coding sequences in the DNA of 16 biopsy samples from PCa patients. Novel mutations were confirmed in the somatic or germline state by Sanger sequencing. Data were then compared to the 1000 Genome Project. PDE, CREB and pCREB protein expression was also studied in all samples, in both normal and abnormal tissue, by immunofluorescence. We identified three previously described PDE sequence variants that were significantly more frequent in PCa. Four novel sequence variations, one each in thePDE4B,PDE6C,PDE7BandPDE10Agenes, respectively, were also found in the PCa samples. Interestingly,PDE10AandPDE4Bnovel variants that were present in 19 and 6% of the patients were found in the tumor tissue only. In patients carrying PDE defects, there was pCREB accumulation (P<0.001), and an increase of the pCREB:CREB ratio (patients 0.97±0.03; controls 0.52±0.03;P-value <0.001) by immunohistochemical analysis. We conclude that PDE sequence variants may play a role in the predisposition and/or progression to PCa at the germline and/or somatic state respectively.

scholarly journals Sequence variants of elaC homolog 2 (Escherichia coli) ( ELAC2 ) gene and susceptibility to prostate cancer in the Health Professionals Follow-Up Study

2008 ◽  
Vol 29 (5) ◽  
pp. 999-1004 ◽  
Author(s):  
Yen-Ching Chen ◽  
Edward Giovannucci ◽  
Peter Kraft ◽  
David J.Hunter
Keyword(s):  
Prostate Cancer ◽  
Escherichia Coli ◽  
Health Professionals ◽  
Sequence Variants ◽  
Follow Up Study

scholarly journals Germline BCL-2 sequence variants and inherited predisposition to prostate cancer

2006 ◽  
Vol 9 (3) ◽  
pp. 284-292 ◽  
Author(s):  
L R Kidd ◽  
A Coulibaly ◽  
T M Templeton ◽  
W Chen ◽  
L O Long ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Sequence Variants ◽  
Inherited Predisposition

scholarly journals Sequence Variants of Toll-Like Receptor 4 and Susceptibility to Prostate Cancer

2005 ◽  
Vol 65 (24) ◽  
pp. 11771-11778 ◽  
Author(s):  
Yen-Ching Chen ◽  
Edward Giovannucci ◽  
Ross Lazarus ◽  
Peter Kraft ◽  
Shamika Ketkar ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Sequence Variants ◽  
Toll Like Receptor ◽  
Toll Like Receptor 4

scholarly journals Cell-Free DNA Variant Sequencing Using Plasma and AR-V7 Testing of Circulating Tumor Cells in Prostate Cancer Patients

Cells ◽  
2021 ◽  
Vol 10 (11) ◽  
pp. 3223
Author(s):  
Verena Lieb ◽  
Amer Abdulrahman ◽  
Katrin Weigelt ◽  
Siegfried Hauch ◽  
Michael Gombert ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Therapy Monitoring ◽  
Brca1 Gene ◽  
Sequence Variants ◽  
Liquid Biopsies ◽  
Treatment Change ◽  
Cell Free Dna ◽  
Free Dna

Prostate cancer (PCa) is the second most common malignant cancer and is a major cause of morbidity and mortality among men worldwide. There is still an urgent need for biomarkers applicable for diagnosis, prognosis, therapy prediction, or therapy monitoring in PCa. Liquid biopsies, including cell-free DNA (cfDNA) and circulating tumor cells (CTCs), are a valuable source for studying such biomarkers and are minimally invasive. In our study, we investigated the cfDNA of 34 progressive PCa patients, via targeted sequencing, for sequence variants and for the occurrence of CTCs, with a focus on androgen receptor splice variant 7 (AR-V7)-positive CTCs. The cfDNA content was associated with overall survival (OS; p = 0.014), disease-specific survival (DSS; p = 0.004), and time to treatment change (TTC; p = 0.001). Moreover, when considering all sequence variants grouped by their functional impact and allele frequency, a significant association with TTC (p = 0.017) was observed. When investigating only pathogenic or likely pathogenic gene variants, variants of the BRCA1 gene (p = 0.029) and the AR ligand-binding domain (p = 0.050) were associated with a shorter TTC. Likewise, the presence of CTCs was associated with a shorter TTC (p = 0.031). The presence of AR-V7-positive CTCs was associated with TTC (p < 0.001) in Kaplan–Meier analysis. Interestingly, all patients with AR-V7-positive CTCs also carried TP53 point mutations. Altogether, analysis of cfDNA and CTCs can provide complementary information that may support temporal and targeted treatment decisions and may elucidate the optimal choice within the variety of therapy options for advanced PCa patients.

Abstract B123: Sequence variants in inflammatory genes, plasma antioxidants, and prostate cancer risk

2010 ◽  
Author(s):  
Jianjun Zhang ◽  
Ishwori Dhakal ◽  
Graham Greene ◽  
Nicholas Lang ◽  
Fred Kadlubar
Keyword(s):  
Prostate Cancer ◽  
Cancer Risk ◽  
Prostate Cancer Risk ◽  
Sequence Variants ◽  
Inflammatory Genes
Sign in / Sign up

Export Citation Format

Share Document